Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of integrase inhibitor-related drug resistance mutations in newly diagnosed ART-naïve HIV patients.

Microbial pathogenesis - 1 Aug 2023

Wang Nan, Xiong Xia, Liu Zhiqi, Zhang Ruixian, Luo Sha, Zhang Hongying, Wu Xuping

Abstract excerpt

BACKGROUND: In China, the recommended treatment regimens for HIV-infected individuals were tenofovir in combination with lamivudine or emtricitabine as NRTIs, efavirenz or rilpivirine as NNRTIs, lopinavir/ritonavir as protease inhibitors, and raltegravir or dolutegravir as INSTIs. The development of drug resistance increases the risk of viral rebound, opportunistic infections, and ultimately treatment failure...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protease Inhibitors

Share to Tenofovir

Source

Identifiers

PMID: 37385569
DOI: 10.1016/j.micpath.2023.106217

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of integrase inhibitor-related drug resistance mutations in newly diagnosed ART-naïve HIV patients.PMID 37385569Read ↗

Drug resistance mutations to integrase inhibitors, proteinase, and reverse transcriptase inhibitors in newly diagnosed HIV-1 infections in Hebei province, China, 2018–2022Semantic proximity Read ↗

Brief communication: characteristics of primary drug resistance in newly diagnosed HIV-infected individuals in Ganzhou, China.Semantic proximity Read ↗

Transmitted HIV-1 Drug Resistance Among Newly Diagnosed Individuals in 31 Provincial-Level Administrative Divisions in China in 2023: A Cross-sectional Survey.Semantic proximity Read ↗

Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China.Semantic proximity Read ↗

Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023.Semantic proximity Read ↗

Evaluation of HIV-1 drug resistance in newly diagnosed individuals in Italy over the period 2017-2023.Semantic proximity Read ↗

Transmitted drug resistance and subtype patterns of viruses from reported new HIV diagnoses in Germany, 2017-2020.Semantic proximity Read ↗

Prevalence and transmission of HIV-1 drug resistance mutations among patients with treatment failure and newly diagnosed people in Liangshan Prefecture, China, in 2021–2023Semantic proximity Read ↗

Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China.Semantic proximity Read ↗

Increased prevalence of pretreatment drug resistance mutations in treatment-naïve people living with HIV-1 in Henan Province, China (2022/23).Semantic proximity Read ↗

Transmitted Drug Resistance Among People Living With HIV-1 in Henan Province, China, 2025Semantic proximity Read ↗

HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018–2024Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.